[Polymorphism in colorectal cancer].
Hazama
Shoichi
S
Department of Digestive Surgery and Surgical Oncology, Molecular Science and Applied Medicine, Yamaguchi University School of Medicine.
Oka
Masaaki
M
Hinoda
Yuji
Y
D000970:Antineoplastic Agents / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D005472:Fluorouracil / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006801:Humans; D000077146:Irinotecan; D008019:Life Style; D020781:Matrix Metalloproteinase 1 / Q000235:genetics; D019278:Matrix Metalloproteinase 3 / Q000235:genetics; D009361:Neoplasm Invasiveness / Q000235:genetics; D009362:Neoplasm Metastasis / Q000235:genetics; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D000077150:Oxaliplatin; D010597:Pharmacogenetics; D020641:Polymorphism, Single Nucleotide; D011355:Prodrugs / Q000627:therapeutic use; D011379:Prognosis; D012307:Risk Factors
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D011355:Prodrugs; D000077150:Oxaliplatin; D000077146:Irinotecan; D019278:Matrix Metalloproteinase 3; D020781:Matrix Metalloproteinase 1; D005472:Fluorouracil; D002166:Camptothecin